2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)

• DOI: 10.1016/j.annonc.2023.09.1028
• Publication Date: 2023-10-20T11:58:05Z
• Authors: P. Barthelemy; Y. Loriot; A. Flechon; M. Gross Goupil; E. Voog; J-C. Eymard; V. Lorgis; D. Pouessel; L. Francois; C. Sajous; D. Chocteau Bouju; A. Guillot; J. Long; E. Amela; C. Josse; M-N. Solbes; P. Lambert; C. Thibault
• Keywords: Clinical endpoint; Metastatic Urothelial Carcinoma